Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Spliceosome mutations: 1 plus 1 does not always equal 2.

Journal article

Pellagatti A. and Boultwood J., (2020), Blood, 136, 1471 - 1472

Splicing factor mutant myelodysplastic syndromes: Recent advances.


Pellagatti A. and Boultwood J., (2020), 75

Recent advances in MDS mutation landscape: Splicing and signalling.

Journal article

Follo MY. et al, (2019), Adv Biol Regul

The impact of spliceosome mutations in MDS

Journal article

Boultwood J. and Pellagatti A., (2019), HemaSphere, 3, 132 - 134

U2AF1 mutations induce oncogenic IRAK4 isoforms and activate innate immune pathways in myeloid malignancies.

Journal article

Smith MA. et al, (2019), Nat Cell Biol, 21, 640 - 650

Application of induced pluripotent stem cell technology for the investigation of hematological disorders.

Journal article

Dolatshad H. et al, (2019), Adv Biol Regul, 71, 19 - 33

Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells.

Journal article

Shastri A. et al, (2018), J Clin Invest, 128, 5479 - 5488

Splicing factor mutations in the myelodysplastic syndromes: target genes and therapeutic approaches.

Journal article

Armstrong RN. et al, (2018), Adv Biol Regul, 67, 13 - 29

Load More